Disc Medicine (IRON) Stock Forecast, Price Target & Predictions
IRON Stock Forecast
Disc Medicine stock forecast is as follows: an average price target of $63.17 (represents a 33.47% upside from IRON’s last price of $47.33) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
IRON Price Target
The average price target for Disc Medicine (IRON) is $63.17 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $75.00 to $43.00. This represents a potential 33.47% upside from IRON's last price of $47.33.
IRON Analyst Ratings
According to 11 Wall Street analysts, Disc Medicine's rating consensus is 'Buy'. The analyst rating breakdown for IRON stock is 0 'Strong Buy' (0.00%), 10 'Buy' (90.91%), 0 'Hold' (0.00%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
Disc Medicine Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Douglas Tsao | H.C. Wainwright | $70.00 | $47.79 | 46.47% | 47.90% |
| Aug 22, 2024 | Tiago Fauth | Wells Fargo | $75.00 | $49.31 | 52.10% | 58.46% |
| Aug 08, 2024 | Danielle Brill | Raymond James | $50.00 | $42.85 | 16.69% | 5.64% |
| Jun 17, 2024 | Evan David Seigerman | BMO Capital | $70.00 | $45.80 | 52.84% | 47.90% |
| May 10, 2024 | Danielle Brill | Raymond James | $43.00 | $29.95 | 43.57% | -9.15% |
| Apr 02, 2024 | Evan David Seigerman | BMO Capital | $50.00 | $34.21 | 46.16% | 5.64% |
| Apr 01, 2024 | Ben Burnett | Stifel Nicolaus | $71.00 | $34.21 | 107.54% | 50.01% |
| Apr 01, 2024 | David Nierengarten | Wedbush | $43.00 | $32.00 | 34.38% | -9.15% |
| Apr 01, 2024 | Danielle Brill | Raymond James | $40.00 | $29.40 | 36.05% | -15.49% |
The latest Disc Medicine stock forecast, released on Sep 16, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $70.00, which represents a 46.47% increase from the stock price at the time of the forecast ($47.79), and a 47.90% increase from IRON last price ($47.33).
Disc Medicine Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 9 |
| Avg Price Target | $72.50 | $65.00 | $56.89 |
| Last Closing Price | $47.33 | $47.33 | $47.33 |
| Upside/Downside | 53.18% | 37.33% | 20.20% |
In the current month, the average price target of Disc Medicine stock is $72.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 53.18% increase as opposed to Disc Medicine's last price of $47.33. This month's average price target is up 11.54% compared to last quarter, and up 27.44% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 22, 2024 | Wells Fargo | - | Overweight | Initialise |
| Aug 08, 2024 | Raymond James | Outperform | Outperform | Hold |
| Jun 14, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jun 13, 2024 | BMO Capital | Outperform | Outperform | Hold |
| May 10, 2024 | Raymond James | Outperform | Outperform | Hold |
| Apr 02, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Apr 01, 2024 | Wedbush | Outperform | Outperform | Hold |
| Apr 01, 2024 | Raymond James | Strong Buy | Outperform | Downgrade |
| Jun 09, 2023 | Raymond James | - | Strong Buy | Upgrade |
Disc Medicine's last stock rating was published by H.C. Wainwright on Sep 16, 2024. The company gave IRON a "Buy" rating, the same as its previous rate.
Disc Medicine Financial Forecast
Disc Medicine Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Disc Medicine's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IRON's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Disc Medicine EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict IRON's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Disc Medicine's previous annual EBITDA (undefined) of $NaN.
Disc Medicine Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-34.14M | $-31.64M | $-31.57M | $-31.04M | $-34.01M | $-27.09M | $-28.33M |
| High Forecast | $-34.14M | $-31.64M | $-31.57M | $-31.04M | $-34.01M | $-24.32M | $-28.33M |
| Low Forecast | $-34.14M | $-31.64M | $-31.57M | $-31.04M | $-34.01M | $-30.40M | $-28.33M |
| Surprise % | - | - | - | - | - | - | - |
Disc Medicine's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IRON's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Disc Medicine SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Disc Medicine's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IRON last annual SG&A of $NaN (undefined).
Disc Medicine EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-1.33 | $-1.23 | $-1.23 | $-1.21 | $-1.33 | $-1.06 | $-1.10 |
| High Forecast | $-1.33 | $-1.23 | $-1.23 | $-1.21 | $-1.33 | $-0.95 | $-1.10 |
| Low Forecast | $-1.33 | $-1.23 | $-1.23 | $-1.21 | $-1.33 | $-1.19 | $-1.10 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Disc Medicine's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IRON previous annual EPS of $NaN (undefined).
Disc Medicine Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FENC | Fennec Pharmaceuticals | $5.26 | $15.75 | 199.43% | Buy |
| ACRV | Acrivon Therapeutics | $7.60 | $22.00 | 189.47% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.48 | $7.00 | 182.26% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.76 | $38.80 | 181.98% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.27 | $6.00 | 164.32% | Buy |
| MLYS | Mineralys Therapeutics | $11.98 | $30.00 | 150.42% | Buy |
| GPCR | Structure Therapeutics | $38.44 | $86.00 | 123.73% | Buy |
| OLMA | Olema Pharmaceuticals | $12.27 | $27.00 | 120.05% | Buy |
| ADAG | Adagene | $2.33 | $5.00 | 114.59% | Buy |
| LRMR | Larimar Therapeutics | $6.81 | $14.50 | 112.92% | Buy |
| BMEA | Biomea Fusion | $8.26 | $13.67 | 65.50% | Buy |
| MLTX | MoonLake Immunotherapeutics | $50.99 | $79.33 | 55.58% | Buy |
| TERN | Terns Pharmaceuticals | $9.63 | $14.25 | 47.98% | Buy |
| IRON | Disc Medicine | $47.35 | $63.17 | 33.41% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| TRDA | Entrada Therapeutics | $14.16 | $18.00 | 27.12% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| CNTA | Centessa Pharmaceuticals | $16.28 | $19.50 | 19.78% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.92 | $3.33 | 14.04% | Buy |
| MORF | Morphic | $56.99 | $57.00 | 0.02% | Hold |
| ANAB | AnaptysBio | $37.50 | $36.33 | -3.12% | Buy |
IRON Forecast FAQ
Is Disc Medicine a good buy?
Yes, according to 11 Wall Street analysts, Disc Medicine (IRON) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 90.91% of IRON's total ratings.
What is IRON's price target?
Disc Medicine (IRON) average price target is $63.17 with a range of $43 to $75, implying a 33.47% from its last price of $47.33. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Disc Medicine stock go up soon?
According to Wall Street analysts' prediction for IRON stock, the company can go up by 33.47% (from the last price of $47.33 to the average price target of $63.17), up by 58.46% based on the highest stock price target, and down by -9.15% based on the lowest stock price target.
Can Disc Medicine stock reach $70?
IRON's highest twelve months analyst stock price target of $75 supports the claim that Disc Medicine can reach $70 in the near future.
What is Disc Medicine's current price target trend?
2 Wall Street analysts forecast a $72.5 price target for Disc Medicine (IRON) this month, up 53.18% from its last price of $47.33. Compared to the last 3 and 12 months, the average price target increased by 37.33% and increased by 20.20%, respectively.
What are Disc Medicine's analysts' financial forecasts?
Disc Medicine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-89.424M (high $-86.66M, low $-92.741M), average SG&A $0 (high $0, low $0), and average EPS is $-3.486 (high $-3.379, low $-3.616). IRON's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-128M (high $-128M, low $-128M), average SG&A $0 (high $0, low $0), and average EPS is $-5.006 (high $-5.006, low $-5.006).